



**Influenza Reagent**  
**Influenza Virus Infectious NIB-131C H1N2v**  
**(A/Bretagne/24241/2021)**  
**NIBSC code: 23/272**  
**Instructions for use**  
**(Version 1.0, Dated 17/02/2026)**

§

**1. INTENDED USE**

Candidate vaccine virus NIB-131C (H1N2v) reagent, a reassortant of A/Bretagne/24241/2021 and NYMC X-157 (H3N2), which was processed in 250µl volumes as liquid stock. The derivation and known passage history of 23/272 are attached.

**2. CAUTION**

**This preparation is not for administration to humans or animals in the human food chain.**

The material is not of human or bovine origin. As with all materials of biological origin, this preparation should be regarded as potentially hazardous to health. It should be used and discarded according to your own laboratory's safety procedures. Such safety procedures should include the wearing of protective gloves and avoiding the generation of aerosols. Care should be exercised in opening ampoules or vials, to avoid cuts.

**3. UNITAGE**

No unitage is assigned to this material

**4. CONTENTS**

Country of origin of biological material: United Kingdom.  
Each ampoule contains 250µl (nominal) of infectious influenza virus as allantoic fluid from SPF embryonated hen's eggs.

**5. STORAGE**

Store in the dark at -70°C or below.  
Material type: Liquid – will be shipped according to the storage and shipping conditions of the product

**6. DIRECTIONS FOR OPENING**

Vials have a screw cap; an internal stopper may also be present. The cap should be removed by turning anti-clockwise. Care should be taken to prevent loss of the contents. Please note: If a stopper is present on removal of the cap, the stopper should remain in the vial or be removed with the cap.

**7. USE OF MATERIAL**

Ready to use

**8. STABILITY**

Reference materials are held at NIBSC within assured, temperature-controlled storage facilities. Reference Materials should be stored on receipt as indicated on the label.

NIBSC follows the policy of WHO with respect to its reference materials.

**9. REFERENCES**

N/A

**10. ACKNOWLEDGEMENTS**

N/A

**11. FURTHER INFORMATION**

Further information can be obtained as follows;  
This material: [enquiries@nibsc.org](mailto:enquiries@nibsc.org)  
WHO Biological Standards:  
<http://www.who.int/biologicals/en/>  
JCTLM Higher order reference materials:  
<http://www.bipm.org/en/committees/jc/jctlm/>  
Derivation of International Units:  
[http://www.nibsc.org/standardisation/international\\_standards.aspx](http://www.nibsc.org/standardisation/international_standards.aspx)  
Ordering standards from NIBSC:  
<http://www.nibsc.org/products/ordering.aspx>  
NIBSC Terms & Conditions:  
[http://www.nibsc.org/terms\\_and\\_conditions.aspx](http://www.nibsc.org/terms_and_conditions.aspx)

**12. CUSTOMER FEEDBACK**

Customers are encouraged to provide feedback on the suitability or use of the material provided or other aspects of our service. Please send any comments to [enquiries@nibsc.org](mailto:enquiries@nibsc.org)

**13. CITATION**

In all publications, including data sheets, in which this material is referenced, it is important that the preparation's title, its status, the NIBSC code number, and the name and address of NIBSC are cited and cited correctly.

**14. MATERIAL SAFETY SHEET**

Classification in accordance with Directive 2000/54/EC, Regulation (EC) No 1272/2008: Not applicable or not classified

<b>Physical and Chemical properties</b>	
Physical appearance: Clear liquid	Corrosive: No
Stable: Yes	Oxidising: No
Hygroscopic: No	Irritant: No
Flammable: No	Handling: See caution, Section 2
Other Live influenza virus (specify):	
<b>Toxicological properties</b>	
Effects of inhalation:	Likelihood of influenza virus infection
Effects of ingestion:	Not established, avoid ingestion
Effects of skin absorption:	Not established, avoid contact with skin
<b>Suggested First Aid</b>	
Inhalation:	Seek medical advice
Ingestion:	Seek medical advice
Contact with eyes:	Wash with copious amounts of water. Seek medical advice
Contact with skin:	Wash thoroughly with water.
<b>Action on Spillage and Method of Disposal</b>	
Spillage of ampoule contents should be taken up with absorbent material wetted with an appropriate virucidal agent. Rinse area with an appropriate virucidal agent followed by water. Absorbent materials used to treat spillage should be treated as biological waste.	



**15. LIABILITY AND LOSS**


In the event that this document is translated into another language, the English language version shall prevail in the event of any inconsistencies between the documents.  
Unless expressly stated otherwise by NIBSC, NIBSC's Standard Terms and Conditions for the Supply of Materials (available at [http://www.nibsc.org/About\\_Us/Terms\\_and\\_Conditions.aspx](http://www.nibsc.org/About_Us/Terms_and_Conditions.aspx) or upon request by the Recipient) ("Conditions") apply to the exclusion of all other terms and are hereby incorporated into this document by reference. The Recipient's attention is drawn in particular to the provisions of clause 11 of the Conditions.

**16. INFORMATION FOR CUSTOMS USE ONLY**

<b>Country of origin for customs purposes*:</b> United Kingdom * Defined as the country where the goods have been produced and/or sufficiently processed to be classed as originating from the country of supply, for example a change of state such as freeze-drying.
<b>Net weight:</b> 0.25g per vial
<b>Toxicity Statement:</b> Non-toxic
<b>Veterinary certificate or other statement</b> if applicable.
<b>Attached:</b> No

**Derivation of NIB-131C H1N2v (A/Bretagne/24241/2021)**

- Strain: A/Bretagne/24241/2021
- Received from the Crick Institute London: E2/E3.
- Passages undertaken at MHRA: one; E2/E3/E1 46720
- Genetic analysis 4:4 with; PR8 "M, PA, PB1 and PB2" genes



Total number of passages since mixed infection= E7  
SPF eggs were used for all passages.

**Passage History of NIB-131C H1N2v (A/Bretagne/24241/2021)**

Cumulative number of passages	Passage numbers at each stage	Lot	Laboratory
E5	E2/E3	E2 (AL2)	Crick Institute, UK
E6	E2/E3/E1	46720	MHRA, UK
E13	E2/E3/E8	47570*	MHRA, UK

\* The HA titre of this virus using 0.7% turkey red blood cells is 1024. The infectious titre is unknown.

Sterility: no visible contamination was detected in a variety of media (tryptose soya broth, thioglycolate broth, Sabouraud's broth and blood agar plates) after 14 days incubation.

The HA and NA sequences of this virus are available at GISAID with the accession number EPI\_ISL\_5933925.

This influenza A virus originated from a zoonotic swine influenza case, and the developed CVV has not had attenuation assessed using the ferret model.